Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

Phase 1

Completed

• Conditions: Liver Transplant; Complications
• Interventions: Drug: N-Acetylecysteine; Drug: Placebo

• Registration Number: NCT03634566
• Lead Sponsor: Ain Shams University

Brief Summary

our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-04-01
• Study First Submitted: 2018-08-13
• Study First Submitted QC: 2018-08-15
• Study First Posted: 2018-08-16
• Primary Completion: 2019-02-01
• Study Completion: 2019-04-01
• Status Verified: 2019-10
• Last Update Submitted: 2020-01-30
• Last Update Posted: 2020-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• ASA I or II donors
• healthy adult

Read More

Exclusion Criteria

• kidney, liver disease
• any contraindications for organ donation

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NAC group	N-Acetylecysteine	Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
Control group	Placebo	Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.

Primary Outcome Measures

Name	Time	Method
Serum lactate	24 hours postoperative

Trial Locations

Locations (1)

Faculty of medicine; 🇪🇬 Cairo, Egypt